All dosages are for adults unless otherwise specified. For details on pediatric dosages, please refer to Chapter 167.
|Glycopyrrolate (Robinul) (does not cross BBB)||++||++||0||+++|
Anticoagulants and Reversal
|Argatroban||Direct thrombin inhibitor||2 μg/kg/min infusion up to 10 μg/kg/min (HIT), 350 μg/kg IV over 2–5 min with 25 μg/kg/min infusion (PCI in patients with HIT)|
|Antithrombin III (ATIII, Thrombate III)||Binds coagulation factors, preventing formation of clot||Determine preinfusion (baseline) antithrombin III concentration and calculate initial (loading) dosage using following formula:|
|Administer dose to increase antithrombin III concentration to a suggested level of 120% of normal using formula|
|Enoxaparin (Lovenox)||Accelerates activity of antithrombin III||30–40 mg SC bid (DVT prophylaxis), 1 mg/kg SC q12 h or 1.5 mg/kg SC q day (Tx of DVT), 1.5 mg/kg/dose SC q12 h (ACS)|
|Protamine||Combines with heparin (strong acid) to form a stable complex (salt)||1 mg protamine per mg of active heparin|
|Warfarin (Coumadin)||Inhibits factors 2, 7, 9, 10 and proteins C and S||5 mg PO, and then maintenance of 2–10 mg PO for goal INR of 2–3|
|Drug||Dose (IV)||Mechanism||Anesthetic considerations|
|Ondansetron (Zofran)||4 mg (adults), 0.1 mg/kg (pediatrics) up to 4 mg||5-HT3 receptor antagonist|
- Prolongs QT interval
- Hepatic clearance
|Granisetron (Kytril)||1 mg (adults), 10 μg/kg (pediatrics)||5-HT3 receptor antagonist|
|Dolasetron (Anzemet)||12.5 mg (adults), 0.35 mg/kg||5-HT3 receptor antagonist|
|Droperidol (Inapsine)||1–2 μg/kg (adults), 0.1 mg/kg (pediatrics)||DA antagonist, blocks release of NE, 5-HT, GABA||Prolongs QT interval (black box warning), hypotension, extrapyramidal effects, avoid in pheochromocytoma, avoid in patients receiving L-dopa therapy|
|Dexamethasone (Decadron)||4–12 mg||Antiemetic mechanism unclear|
- Administer with caution in patients with DM
- Useful if airway trauma during repeated intubations
- Useful as antiemetic (4 mg)
|Metoclopramide (Reglan)||0.25 mg/kg||DA antagonist centrally, peripheral cholinomimetic|
- Avoid in patients with pheochromocytoma
- Can cause extrapyramidal side effects, neuroleptic malignant syndrome
- Does not affect gastric pH
|Promethazine (Phenergan)||12.5–25 mg|
- H1 receptor antagonist
- DA blocker
- Partial alpha-blocker
- Respiratory depression
- CNS depression
- Rare neuroleptic malignant syndrome
|Drug||Dosage||Mechanism of action|
|Aminocaproic acid (Amicar)|
- Acute bleeding: 4–5 g during the first hour, followed by 1 g/h for 8 h or until bleeding controlled (maximum daily dose: 30 g)
- Thrombocytopenia: 0.1 g/kg over 30–60 min
|Blocks activation of plasminogen ...|
Log In to View More
If you don't have a subscription, please view our individual subscription options below to find out how you can gain access to this content.
Want remote access to your institution's subscription?
Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.
If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
AccessAnesthesiology Full Site: One-Year Subscription
Connect to the full suite of AccessAnesthesiology content and resources including procedural videos, interactive self-assessment, real-life cases, 20+ textbooks, and more
Pay Per View: Timed Access to all of AccessAnesthesiology
24 Hour Subscription $34.95
48 Hour Subscription $54.95
Pop-up div Successfully Displayed
This div only appears when the trigger link is hovered over.
Otherwise it is hidden from view.